淋巴血管侵犯
医学
旁侵犯
内科学
外科肿瘤学
结直肠癌
阶段(地层学)
肿瘤科
比例危险模型
病态的
化疗
辅助化疗
辅助治疗
生存分析
癌症
胃肠病学
转移
乳腺癌
古生物学
生物
作者
Linjie Zhang,Yuxiang Deng,Songran Liu,Weili Zhang,Zhigang Hong,Zhenhai Lu,Zhizhong Pan,Xiaojun Wu,Jianhong Peng
出处
期刊:BMC Cancer
[Springer Nature]
日期:2023-01-03
卷期号:23 (1)
被引量:6
标识
DOI:10.1186/s12885-022-10416-7
摘要
Abstract Background Lymphovascular invasion (LVI) and perineural invasion (PNI) can indicate poor survival outcomes in colorectal cancer, but few studies have focused on stage III colon cancer. The current study aimed to confirm the prognostic value of LVI and PNI and identify patients who could benefit from a complete duration of adjuvant chemotherapy based on the two pathological factors. Methods We enrolled 402 consecutive patients with stage III colon cancer who received colon tumor resection from November 2007 to June 2016 at Sun Yat-sen University Cancer Center. Survival analyses were performed by using Kaplan–Meier method with log-rank tests. Risk factors related to disease-free survival (DFS) and overall survival (OS) were identified through Cox proportional hazards analysis. Results 141 (35.1%) patients presented with LVI, and 108 (26.9%) patients with PNI. The LVI-positive group was associated with poorer 3-year DFS (86.5% vs. 76.3%, P = 0.001) and OS (96.0% vs. 89.1%, P = 0.003) rates compared with the LVI-negative group. The PNI-positive group showed a worse outcome compared with the PNI-negative group in 3-year DFS rate (72.5% vs. 86.7%, P < 0.001). Moreover, LVI-positive group present better 3-year DFS and OS rate in patients completing 6–8 cycles of adjuvant chemotherapy than those less than 6 cycles (3-year DFS: 80.0% vs. 64.9%, P = 0.019; 3-year OS: 93.2% vs. 76.3%, P = 0.002). Conclusions LVI is a superior prognostic factor to PNI in stage III colon cancer patients undergoing curative treatment. PNI status can noly predict the 3-year DFS wihout affecting the 3-year OS. Furthermore, LVI also represents an effective indicator for adjuvant chemotherapy duration.
科研通智能强力驱动
Strongly Powered by AbleSci AI